Share This Article:

Ocular Surface Disease Index in Glaucomatous Patients Treated with Bimatoprost

Abstract Full-Text HTML XML Download Download as PDF (Size:209KB) PP. 36-39
DOI: 10.4236/ojoph.2014.42007    1,698 Downloads   2,441 Views  
Author(s)    Leave a comment

ABSTRACT


Objectives: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of bimatoprost 0.03%/timolol 0.50%, timolol 0.50% or bimatoprost 0.01% eye drops. Methods: This is a prospective, one center, open-label clinical trial. It was performed on 60 glaucoma patients between 01-01-2012 and 12-31-2012. These patients were randomly divided in three subgroups: bimatoprost 0.03%/timolol 0.50% fixed combination, timolol 0.50% and bimatoprost 0.01%. The Ocular Surface Disease Index (O.S.D.I.) was evaluated in all the glaucomatous patients of the three subgroups at basal time and after 6 and 12 months. All the results were statistically evaluated by Student t-test and one-way ANOVA. The results were considered statistically significant if p < 0.05. Results: All of the patients ended the clinical trial. There was no statistical significant difference between patients treated with the bimatoprost 0.03%/timolol 0.50% fixed combination and timolol 0.50% eye drops alone (p = 0.845). Instead, there was a statistically significant difference between bimatoprost 0.01% and bimatoprost 0.03%/timolol 0.50% patients (p = 0.05) and between bimatoprost 0.01% and timolol 0.50% eye drops alone (p = 0.049). Conclusions: This is a clinical trial based not on the hypotonising effect of these drugs but on their tolerability. The drug which showed the best tolerability is bimatoprost 0.01%.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Giuffrè, I. (2014) Ocular Surface Disease Index in Glaucomatous Patients Treated with Bimatoprost. Open Journal of Ophthalmology, 4, 36-39. doi: 10.4236/ojoph.2014.42007.

References

[1] Russ, H.H., Nogueira-Filho, P.A., Barros Jde, N., et al. (2013) Ocular Surface Evaluation in Patients Treated with a Fixed Combination of Prostaglandin Analogues with 0.5% Timolol Maleate Topical Monotherapy: A Randomized Clinical Trial. Clinics (Sao Paulo), 68, 1318-1324.
http://dx.doi.org/10.6061/clinics/2013(10)05
[2] Nixon, D.R. (2013) A Randomized, Prospective Study of Bimatoprost 0.01% or Travoprost/Timolol in Patients Previously Treated with Latanoprost and Timolol to Reduce Intraocular Pressure. Journal of Ocular Pharmacology and Therapeutics, 29, 876-881.
http://dx.doi.org/10.1089/jop.2013.0108
[3] Pfennigsdorf, S., de Jong, L., Makk, S., et al. (2013) A Combined Analysis of Five Observational Studies Evaluating the Efficacy and Tolerability of Bimatoprost/Timolol Fixed Combination in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Journal of Clinical Ophthalmology, 7, 1219-1225.
http://dx.doi.org/10.2147/OPTH.S41885
[4] Shafiee, A., Bowman, L.M., Hou, E., et al. (2013) Ocular Pharmacokinetics of Bimatoprost Formulated in DuraSite Compared to Bimatoprost 0.03% Ophthalmic Solution in Pigmented Rabbit Eyes. Journal of Clinical Ophthalmology, 7, 1549-1556.
http://dx.doi.org/10.2147/OPTH.S48766
[5] Campbell, J.H., Schwartz, G., Labounty, B., et al. (2013) Comparison of Adherence and Persistence with Bimatoprost 0.01% versus Bimatoprost 0.03% Topical Ophthalmic Solutions. Current Medical Research and Opinion, 29, 1201-1209.
http://dx.doi.org/10.1185/03007995.2013.815160
[6] Wong, W.B., Patel, V.D., Kowalski, J.W., et al. (2013) An Adherence Based Cost-Consequence Model Comparing Bimatoprost 0.01% to Bimatoprost 0.03%. Current Medical Research and Opinion, 29, 1191-1200.
http://dx.doi.org/10.1185/03007995.2013.815159
[7] Alany, R.G. (2013) Adherence, Persistence and Cost-Consequence Comparison of Bimatoprost Topical Ocular Formulations. Current Medical Research and Opinion, 29, 1187-1189.
http://dx.doi.org/10.1185/03007995.2013.818968
[8] Stewart, W.C., Kolker, A.E., Stewart, J.A., et al. (2003) Conjunctival Hyperemia in Healthy Subjects after Short-Term Dosing with Latanoprost, Bimatoprost, and Travoprost. American Journal of Ophthalmology, 135, 314-320.
http://dx.doi.org/10.1016/S0002-9394(02)01980-3
[9] Johnstone, M.A. (1997) Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost. American Journal of Ophthalmology, 124, 544-547.
[10] Kook, M.S. and Lee, K. (2000) Increased Eyelid Pigmentation Associated with the Use of Latanoprost. American Journal of Ophthalmology, 129, 804-806.
http://dx.doi.org/10.1016/S0002-9394(00)00402-5
[11] Herreras, J.M., Pastor, J.C., Calonge, M., et al. (1992) Ocular Surface Alteration after Long-Term Treatment with Antiglaucomatous Drug. Ophthalmology, 99, 1082-1088.
http://dx.doi.org/10.1016/S0161-6420(92)31847-0
[12] Nuzzi, R., Finazzo, C. and Cerruti, A. (1998) Adverse Effects of Topical Antiglaucomatous Medications on the Conjunctiva and the Lacrymal. International Ophthalmology, 22, 31-35.
http://dx.doi.org/10.1023/A:1006051725115
[13] Broadway, D.C., Grierson, I., O’Brien, C., et al. (1994) Adverse Effects of Topical Antiglaucoma Medication. The Conjunctival Cell Profile. Archives of Ophthalmology, 112, 1437-1445.
http://dx.doi.org/10.1001/archopht.1994.01090230051020
[14] Arici, M.K., Arici, D.S., Topalkara, A., et al. (2000) Adverse Effects of Topical Antiglaucoma Drugs on the Ocular Surface. Journal of Clinical & Experimental Ophthalmology, 28, 113-117.
http://dx.doi.org/10.1046/j.1442-9071.2000.00237.x

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.